SCHEMBL928055

SCHEMBL928055

OCc1nn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.58
PDE5A O76074 3/20 0.57
CYP1A2 P05177 3/20 0.57
CYP2D6 P10635 3/20 0.57
KDM4E B2RXH2 2/20 0.57
CYP3A4 P08684 2/20 0.57
NPC1 O15118 1/20 0.57
GMNN O75496 1/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
MAPT P10636 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
NFKB1 P19838 1/20 0.57
MAPK1 P28482 1/20 0.57
CYP2C19 P33261 1/20 0.57
RAB9A P51151 1/20 0.57
BLM P54132 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29562418 1.00 SLC16A3 (0.58) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
Water SCHEMBL9265852 0.98 SLC16A3 (0.56) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL928140 0.89 PTGER4 (0.50) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL929442 0.88 PTGER4 (0.51) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL927912 0.88 SLC16A3 (0.50) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL3426837 0.87 SLC16A3 (0.55) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL927918 0.85 CNR1 (0.64) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL29562238 0.85 CNR1 (0.56) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL928072 0.85 CNR1 (0.56) SLC16A3PDE5ACYP1A2CYP2D6KDM4E
SCHEMBL929057 0.84 TDP1 (0.48) SLC16A3PDE5ACYP1A2CYP2D6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106518769-A Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates 方济各安吉利克化学联合股份有限公司 2017-03-22 CN claimed
CN-102471281-B Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2014-10-15 CN claimed
EP-2462119-B1 Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required Magnesium intermediates ACRAF (IT) 2014-06-11 EP claimed
EP-2462118-B1 Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required Magnesium intermediates ACRAF (IT) 2014-06-11 EP claimed
US-8354544-B2 Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required magnesium intermediates AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-01-15 US claimed
US-8350052-B2 Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required magnesium intermediates AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-01-08 US claimed
US-20120220636-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F.S.P.A. (IT) 2012-08-30 US claimed
EP-2480224-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2012-08-01 EP claimed
US-20120184752-A1 PROCESS FOR THE PREPARATION OF 1-BENZYL-3-HYDROXYMETHYL-1H-INDAZOLE AND ITS DERIVATIVES AND REQUIRED MAGNESIUM INTERMEDIATES AZIENDE CHIM, RIUN, ANG, FRANC. A.C.R.A.F. S.p.A. (IT) 2012-07-19 US claimed
CN-102573827-A Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases ACRAF 2012-07-11 CN claimed
US-20120149912-A1 PROCESS FOR THE PREPARATION OF 1-BENZYL-3-HYDROXYMETHYL-1H-INDAZOLE AND ITS DERIVATIVES AND REQUIRED MAGNESIUM INTERMEDIATES AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) 2012-06-14 US claimed
CN-102471282-A 1-benzyl-3-hydroxymethyl-1H-indazole and derivatives thereof and process for the preparation of the desired magnesium intermediate ACRAF 2012-05-23 CN claimed
CN-102471281-A 1-benzyl-3-hydroxymethyl-1H-indazole and derivatives thereof and process for the preparation of the desired magnesium intermediate ACRAF 2012-05-23 CN claimed
WO-2011036047-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2011-03-31 WO claimed
CN-1842332-A Compounds, compositions and methods HIF BIO INC (US) 2006-10-04 CN claimed
JP-2240065-A None JP disclosed
EP-3990433-B1 PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES TRANSLATUM MEDICUS INC (CA) 2026-05-20 EP disclosed
CN-1044810-A Ethers of 1-benzyl-3-hydroxymethyl-indazole and aliphatic-2-hydroxy acids ACRAF (IT) 1990-08-22 CN disclosed
EP-0382276-A2 Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 1990-08-16 EP disclosed
EP-0382276-A2 Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 1990-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220636-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES ACE, ACE2, CCL11 SLC16A3 2310/4885PDE5A 687/4885CYP1A2 798/4885
US-20120184752-A1 PROCESS FOR THE PREPARATION OF 1-BENZYL-3-HYDROXYMETHYL-1H-INDAZOLE AND ITS DERIVATIVES AND REQUIRED MAGNESIUM INTERMEDIATES CYP2E1, CYP3A4, CYP1A1 SLC16A3 3101/4885PDE5A 4261/4885CYP1A2 13/4885
US-20120149912-A1 PROCESS FOR THE PREPARATION OF 1-BENZYL-3-HYDROXYMETHYL-1H-INDAZOLE AND ITS DERIVATIVES AND REQUIRED MAGNESIUM INTERMEDIATES CYP2E1, CYP3A4, CYP1B1 SLC16A3 2646/4885PDE5A 4209/4885CYP1A2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.